207 related articles for article (PubMed ID: 28356599)
21. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract][Full Text] [Related]
22. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
23. Clinical Application of Next-Generation Sequencing-Based Panel to
Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
[TBL] [Abstract][Full Text] [Related]
24. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
25. Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients.
Castillo P; Marginet M; Jares P; García M; Gonzalvo E; Arance A; García A; Alos L; Teixido C
Explor Target Antitumor Ther; 2020; 1(2):101-108. PubMed ID: 36046072
[TBL] [Abstract][Full Text] [Related]
26. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S
BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877
[TBL] [Abstract][Full Text] [Related]
27. Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing.
McEvoy AC; Wood BA; Ardakani NM; Pereira MR; Pearce R; Cowell L; Robinson C; Grieu-Iacopetta F; Spicer AJ; Amanuel B; Ziman M; Gray ES
J Mol Diagn; 2018 Mar; 20(2):240-252. PubMed ID: 29305225
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
29. Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
Craig DJ; Morrison T; Khuder SA; Crawford EL; Wu L; Xu J; Blomquist TM; Willey JC
BMC Cancer; 2019 Nov; 19(1):1081. PubMed ID: 31711466
[TBL] [Abstract][Full Text] [Related]
30. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
Siroy AE; Boland GM; Milton DR; Roszik J; Frankian S; Malke J; Haydu L; Prieto VG; Tetzlaff M; Ivan D; Wang WL; Torres-Cabala C; Curry J; Roy-Chowdhuri S; Broaddus R; Rashid A; Stewart J; Gershenwald JE; Amaria RN; Patel SP; Papadopoulos NE; Bedikian A; Hwu WJ; Hwu P; Diab A; Woodman SE; Aldape KD; Luthra R; Patel KP; Shaw KR; Mills GB; Mendelsohn J; Meric-Bernstam F; Kim KB; Routbort MJ; Lazar AJ; Davies MA
J Invest Dermatol; 2015 Feb; 135(2):508-515. PubMed ID: 25148578
[TBL] [Abstract][Full Text] [Related]
31. Validation of an NGS mutation detection panel for melanoma.
Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
[TBL] [Abstract][Full Text] [Related]
32. Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use.
Shi Z; Lopez J; Kalliney W; Sutton B; Simpson J; Maggert K; Liu S; Wan J; Stack MS
PLoS One; 2022; 17(4):e0266914. PubMed ID: 35446881
[TBL] [Abstract][Full Text] [Related]
33. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
[TBL] [Abstract][Full Text] [Related]
34. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
Lokhandwala PM; Tseng LH; Rodriguez E; Zheng G; Pallavajjalla A; Gocke CD; Eshleman JR; Lin MT
BMC Cancer; 2019 Jul; 19(1):665. PubMed ID: 31277584
[TBL] [Abstract][Full Text] [Related]
35. Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
[TBL] [Abstract][Full Text] [Related]
36. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma.
Zhu ML; Zhou L; Sadri N
Virchows Arch; 2018 Sep; 473(3):371-377. PubMed ID: 29926184
[TBL] [Abstract][Full Text] [Related]
37. A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.
Louveau B; Jouenne F; Têtu P; Sadoux A; Gruber A; Lopes E; Delyon J; Serror K; Marco O; Da Meda L; Ndiaye A; Lermine A; Dumaz N; Battistella M; Baroudjian B; Lebbe C; Mourah S
Target Oncol; 2020 Dec; 15(6):759-771. PubMed ID: 33151472
[TBL] [Abstract][Full Text] [Related]
38. Age-related next-generation sequencing mutational analysis in 1196 melanomas.
Santamaria-Barria JA; Matsuba C; Khader A; Scholar AJ; Garland-Kledzik M; Fischer TD; Essner R; Salomon MP; Mammen JMV; Goldfarb M
J Surg Oncol; 2023 Jun; 127(7):1187-1195. PubMed ID: 36938777
[TBL] [Abstract][Full Text] [Related]
39. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
40. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]